| Document |
Document Title |
|
WO/2024/059563A1 |
Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
|
|
WO/2024/041503A1 |
The present invention discloses compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are processes for ...
|
|
WO/2024/032584A1 |
The present invention relates to a protein tyrosine kinase inhibitor for treating protein tyrosine kinase-mediated proliferative diseases or symptoms, such as ocular diseases and malignant tumors accompanied by pathological neoangiogenes...
|
|
WO/2024/016826A1 |
The present invention relates to the field of organic synthetic medicines, and in particular, to a 6-position substituted 3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide compound, having a general formula as follows: (I). The 6-positio...
|
|
WO/2023/241618A1 |
Disclosed are a series of aminopyrimidine compounds and use thereof, and specifically disclosed are a compound represented by formula (XI), a stereoisomer thereof and a pharmaceutically acceptable salt thereof, and use thereof.
|
|
WO/2023/237116A1 |
The present invention discloses a protein degrader such as a GSPT1 degrader and use thereof, particularly use in the prevention and/or treatment of diseases.
|
|
WO/2023/213965A1 |
The present invention relates to compounds according to Formula (I) and their use as CDK8 and/or CDK19 inhibitors.
|
|
WO/2023/209191A1 |
The invention concerns a novel class of Prolyl oligopeptidase binding ligands, a pharmaceutical composition comprising same, the use of said ligands as medicaments, particularly, but not exclusively to promote autophagy and/or treat a di...
|
|
WO/2023/212693A1 |
The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3 kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceutic...
|
|
WO/2023/210741A1 |
The present invention addresses the problem of providing a medicine capable of treating and/or preventing a disease associated with oxidative stress through the inhibition of a protein-protein interaction between Keap1 and Nrf2 to activa...
|
|
WO/2023/165459A1 |
Provided are certain antiviral agents, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2023/165525A1 |
Provided are DGKalpha inhibitors and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with DGKalpha.
|
|
WO/2023/158602A1 |
Disclosed are compounds of Formula I including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein G, Z, L, J, A and T are as defined in the disclosure. Also disclosed are compositions containing the compound...
|
|
WO/2023/143389A1 |
The present disclosure relates to a fused heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, the present disclosure relates to a fused heterocyclic compound represented by general formu...
|
|
WO/2023/064058A1 |
Compounds of formula I, that modulate DCAF15 and induce RBM39 protein degradation, pharmaceutical compositions containing these compounds, and methods of using these compounds for treating diseases associated with RBM39 protein activity ...
|
|
WO/2023/036282A1 |
A crystal form of a pyrimidine heterocyclic compound and a preparation method therefor. Specifically disclosed are a preparation method for and application of a compound of formula (II) and the crystal form thereof.
|
|
WO/2023/025112A1 |
Provided are an isoindolinone compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, and a use thereof in the treatment of proliferative diseases. Further provided is a pharmaceutical composition co...
|
|
WO/2023/016434A1 |
Provided are compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are pharmaceutical compositions compr...
|
|
WO/2023/272720A1 |
PD-L1 inhibitors of various compound formulas, both generically and specifically are disclosed. Methods of making such PD-L1 inhibitor compounds are disclosed, both generically and specifically. Methods of using such PD-L1 inhibitor comp...
|
|
WO/2022/249074A1 |
The present invention discloses a novel fungicidal composition comprising at least one compound of formula (I) or an agriculturally acceptable salt thereof as a component (1), Formula (I) wherein, R, A, L1, R1, and n are as defined in th...
|
|
WO/2022/145459A1 |
The present invention addresses the problem of providing a compound having Nrf2-activation action. Provided are: compounds represented by general formula (I), or compounds of the lower-polarity group among two groups of diastereomers in ...
|
|
WO/2022/143479A1 |
Provided are a solid form of a compound, a preparation method therefor and the use thereof, which belong to the field of pharmaceutical chemistry. The solid form comprises a co-crystal of the compound and cinnamamide, or a tromethamine s...
|
|
WO/2022/119823A1 |
Positive allosteric modulators (PAMs) of Mas-related G protein-coupled receptor X1 (MRGPRX1) and their use for treating neuropathic pain is disclosed.
|
|
WO/2022/105636A1 |
Disclosed are a spiro compound, a pharmaceutical composition containing same, and the use thereof. The spiro compound interferes with interaction between the protein menin and MLL1, MLL2 or MLL fusion oncoproteins, and is expected to be ...
|
|
WO/2022/038066A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing these compounds.
|
|
WO/2021/238587A1 |
A micromolecular oxathiazine derivative, which belongs to the field of organic synthesis medicines and has the general formula as shown below: the micromolecular oxathiazine derivative can be used as a positive allosteric modulator of an...
|
|
WO/2021/238588A1 |
An oxathiazine compound, of which the general formula is as follows. The oxathiazine compound can be used as a positive allosteric modulator of an AMPA receptor, and can positively modulate the AMPA receptor and make the conformation mor...
|
|
WO/2021/229152A1 |
The present invention relates to a compound of formula (I) or (II) wherein R1, R2, R3, R4, R5, R23, R24, R25, R26, R27, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of fo...
|
|
WO/2021/226003A1 |
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related disea...
|
|
WO/2021/180181A1 |
A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/170774A1 |
A compound of formula (I) : wherein Z, Y1,Y2,(Formula II)R1 to R7 are as defined in the description, its optical isomers, and addition salts thereof with a pharmaceutically acceptable base. Medicaments.
|
|
WO/2021/143821A1 |
A fused heteroaryl derivative, a preparation method therefor, and an application thereof in medicine. In particular, provided are a fused heteroaryl derivative as shown in general formula (I-1), a preparation method therefor, a pharmaceu...
|
|
WO/2021/063967A1 |
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...
|
|
WO/2021/037401A1 |
The invention relates to dibenzofuran derivatives which are substituted with electron-poor heteroaryl groups, and to electronic devices, in particular organic electroluminescent devices containing said compounds as triplet matrix materials.
|
|
WO/2021/018237A1 |
Provided are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well a...
|
|
WO/2021/002473A1 |
The invention addresses the problem of providing a compound having Nrf2-activation action. The invention is the compound represented by general formula (I), a salt thereof, or a solvate thereof. General formula (I): In the formula: R1a a...
|
|
WO/2020/226295A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic layer placed between the first electrode and the second electrode;...
|
|
WO/2020/208509A1 |
The present invention discloses a compound of formula (I), wherein, R1, L1,A, k, L2, W, L4, R5, R8 and R9 are as defined in the detailed description. The present invention further discloses a process for preparing the compound of formula...
|
|
WO/2020/208511A1 |
The present invention discloses a compound of formula (I), Formula (I) wherein, R1, L1,A, L2, W1, R2f, R3f, Q, and R10 are as defined in the detailed description. The present invention also relates to a process for preparing the compound...
|
|
WO/2020/146470A1 |
The present invention provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Such target proteins can be any protein involved in the pathway of a disease or disorder, such as but not l...
|
|
WO/2020/132648A1 |
Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related...
|
|
WO/2020/128925A1 |
The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing ...
|
|
WO/2020/103897A1 |
A heterocyclic fused pyrimidine derivative, a pharmaceutical composition thereof, and an application thereof. A heterocyclic fused pyrimidine derivative (I), and an isomer, prodrug, stable isotope derivative, or pharmaceutically acceptab...
|
|
WO/2020/064002A1 |
The present invention relates to a polysubstituted isoindoline compound as shown in general formula (I), and a preparation method, a pharmaceutical composition and the use thereof. In particular, the polysubstituted isoindoline compound ...
|
|
WO/2020/041169A2 |
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as...
|
|
WO/2020/021215A1 |
The present invention relates to deuterated derivatives of lanifibranor, in particular for use in therapy, specifically in the treatment of fibrotic diseases.
|
|
WO/2019/164301A1 |
The present specification provides a compound of chemical formula 1 and an organic light emitting diode comprising same.
|
|
WO/2019/122393A1 |
The present disclosure relates to the use of hydroxyisoxazolines and derivatives thereof as fungicide. It also relates to new hydroxyisoxazolines derivatives, their use as fungicide and compositions comprising thereof.
|
|
WO/2019/123007A1 |
Disclosed is an aryl hydrocarbon receptor modulator of formula (I), and a pharmaceutically acceptable salt thereof, wherein R' is H, CN, CH2(OH)R0, CmH2m+1, CnH2n-1, CnH2n-3, formula (IV), formula (II), or formula (II); the two Ra are in...
|
|
WO/2019/121541A1 |
The invention relates to substituted N-heterocyclyl- and N-heteroaryl-tetrahydropyrimidinones of general formula (I) or the salts (I) thereof, wherein the groups in general formula (I) are as defined in the description, and to the use of...
|
